v3.26.1
SEGMENT INFORMATION (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Segment Reporting Information [Line Items]    
Royalty revenues $ 570 $ 501
Operating expenses    
Research and development 19,237 30,946
General and administrative 11,082 13,192
Operating loss (29,749) (43,637)
Income tax expense 4 4
Loss from continuing operations (26,736) (39,807)
Net loss (26,483) (39,834)
Reportable Segment    
Operating expenses    
Research and development 2,994 3,413
General and administrative 11,082 13,192
Total operating expenses 30,319 44,138
Operating loss (29,749) (43,637)
Other income, net 3,017 3,834
Loss from continuing operations before income taxes (26,732) (39,803)
Income tax expense 4 4
Loss from continuing operations (26,736) (39,807)
Income (loss) from discontinued operations, net of income taxes 253 (27)
Net loss (26,483) (39,834)
Reportable Segment | Royalty revenues    
Segment Reporting Information [Line Items]    
Royalty revenues 570 501
Reportable Segment | Repibresib (VYN201)    
Operating expenses    
Research and development 8,487 16,271
Reportable Segment | VYN202    
Operating expenses    
Research and development $ 7,756 $ 11,262